Axonis Therapeutics
Axonis Therapeutics is a neuro-focused biotechnology company developing medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries from Boston Children’s Hospital, Harvard, and Laval University. It develops a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies.
Domain
axonis.us
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$115.0M
Founded
2019
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does Axonis Therapeutics use?+
Axonis Therapeutics uses 16 technologies including Astra, Contact Form 7, Elementor.
What industry is Axonis Therapeutics in?+
Axonis Therapeutics operates in the Biotechnology industry.
Where is Axonis Therapeutics based?+
Axonis Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026